| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
11,270,000 |
| Market
Cap: |
280.74(M) |
| Last
Volume: |
197,427 |
Avg
Vol: |
196,886 |
| 52
Week Range: |
$13.82 - $26.5 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile XOMA is a biotech royalty aggregator. Co. has a portfolio of economic rights to milestone and royalty payments associated with partnered pre-commercial therapeutic candidates. Co.'s portfolio was built through licensing its proprietary products and platforms from its discovery and development business, combined with acquisitions of rights to milestones and royalties.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
6,750 |
117,800 |
| Total Buy Value |
$0 |
$0 |
$100,454 |
$2,088,813 |
| Total People Bought |
0 |
0 |
2 |
3 |
| Total Buy Transactions |
0 |
0 |
6 |
21 |
| Total Shares Sold |
0 |
0 |
0 |
27,000 |
| Total Sell Value |
$0 |
$0 |
$0 |
$809,425 |
| Total People Sold |
0 |
0 |
0 |
2 |
| Total Sell Transactions |
0 |
0 |
0 |
2 |
| End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
• – – |
2014-08-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
26,748 |
98,769 |
|
- |
|
| Kurland Fred |
CFO & VP Finance |
• – – |
2014-08-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
19,064 |
81,664 |
|
- |
|
| Varian John |
CEO |
• • – |
2014-08-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
94,574 |
380,187 |
|
- |
|
| Scannon Patrick J Md Phd |
Exec. VP & CSO |
• • – |
2014-08-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,264 |
97,810 |
|
- |
|
| Scannon Patrick J Md Phd |
Exec. VP & CSO |
• • – |
2014-08-01 |
4 |
AS |
$3.83 |
$19,162 |
D/D |
(5,000) |
81,546 |
|
- |
|
| Varian John |
CEO |
• • – |
2014-07-15 |
4 |
AS |
$4.03 |
$40,285 |
D/D |
(10,000) |
285,613 |
|
- |
|
| Varian John |
CEO |
• • – |
2014-07-15 |
4 |
OE |
$1.24 |
$12,400 |
D/D |
10,000 |
295,613 |
|
- |
|
| Scannon Patrick J Md Phd |
Exec. VP & CSO |
• • – |
2014-07-01 |
4 |
AS |
$4.68 |
$23,411 |
D/D |
(5,000) |
86,546 |
|
- |
|
| Neal James R |
VP Business Development |
– – – |
2014-06-30 |
5 |
A |
$4.36 |
$2,590 |
D/D |
594 |
153,264 |
|
- |
|
| Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
• – – |
2014-06-30 |
5 |
A |
$4.36 |
$2,058 |
D/D |
472 |
76,382 |
|
- |
|
| Varian John |
CEO |
• • – |
2014-06-16 |
4 |
AS |
$4.54 |
$45,410 |
D/D |
(10,000) |
285,613 |
|
- |
|
| Varian John |
CEO |
• • – |
2014-06-16 |
4 |
OE |
$1.24 |
$12,400 |
D/D |
10,000 |
295,613 |
|
- |
|
| Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
• – – |
2014-06-16 |
4 |
AS |
$4.54 |
$52,595 |
D/D |
(11,580) |
72,021 |
|
- |
|
| Limber Joseph M |
Director |
– • – |
2014-05-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,800 |
16,800 |
|
- |
|
| Bowes William K Jr |
Director |
– • – |
2014-05-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,600 |
26,868 |
|
- |
|
| Van Ness W Denman |
Director |
– • – |
2014-05-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,300 |
32,652 |
|
- |
|
| Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
• – – |
2014-05-28 |
4 |
S |
$4.22 |
$7,533 |
D/D |
(1,785) |
83,601 |
|
- |
|
| Rubin Paul D |
Sr. VP Clinical Dev. & CMO |
• – – |
2014-05-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,667 |
85,386 |
|
- |
|
| Wyszomierski Jack L |
Director |
– • – |
2014-05-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,600 |
25,797 |
|
- |
|
| Walbert Timothy P |
Director |
– • – |
2014-05-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,600 |
25,797 |
|
- |
|
| Baker Bros. Advisors (gp) Llc |
Director |
– • • |
2014-05-22 |
4 |
A |
$0.00 |
$0 |
I/I |
25,200 |
518,849 |
|
- |
|
| Limber Joseph M |
Director |
– • – |
2014-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
8,400 |
14,000 |
|
- |
|
| Bowes William K Jr |
Director |
– • – |
2014-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
8,400 |
21,268 |
|
- |
|
| Walbert Timothy P |
Director |
– • – |
2014-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
8,400 |
20,197 |
|
- |
|
| Wyszomierski Jack L |
Director |
– • – |
2014-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
8,400 |
20,197 |
|
- |
|
354 Records found
|
|
Page 14 of 15 |
|
|
0.17 (0.68%) 
